tbuckley/cabot-search huggingface dataset:
Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Authors: Toni T. Seppälä, Jacquelyn W. Zimmerman, Reecha Suri, Haley Zlomke, Gabriel D. Ivey, Annamaria Szabolcs, Christopher R. Shubert, John L. Cameron, William R. Burns, Kelly J. Lafaro, Jin He, Christopher L. Wolfgang, Ying S. Zou, Lei Zheng, David A. Tuveson, James R. Eshlemann, David P. Ryan, Alec C. Kimmelman, Theodore S. Hong, David T. Ting, Elizabeth M. Jaffee, Richard A. Burkhart
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Patient-derived organoids (PDO) are a promising technology to support precision medicine initiatives for patients with pancreatic ductal adenocarcinoma (PDAC). PDOs may improve clinical next-generation sequencing (NGS) and enable rapid ex vivo chemotherapeutic screening (pharmacotyping). Experimental Design: PDOs were derived from tissues obtained during surgical resection and endoscopic biopsies and studied with NGS and pharmacotyping. PDO-specific pharmacotype is assessed prospectively as a predictive biomarker of clinical therapeutic response by leveraging data from a randomized controlled clinical trial. Results: Clinical sequencing pipelines often fail to detect PDAC-associated somatic mutations in surgical specimens that demonstrate a good pathologic response to previously administered chemotherapy. Sequencing the PDOs derived from these surgical specimens, after biomass expansion, improves the detection of somatic mutations and enables quantification of copy number variants. The detection of clinically relevant mutations and structural variants is improved following PDO biomass expansion. On clinical trial, PDOs were derived from biopsies of treatment-naïve patients prior to treatment with FOLFIRINOX (FFX). Ex vivo PDO pharmacotyping with FFX components predicted clinical therapeutic response in these patients with borderline resectable or locally advanced PDAC treated in a neoadjuvant or induction paradigm. PDO pharmacotypes suggesting sensitivity to FFX components were associated with longitudinal declines of tumor marker, carbohydrate-antigen 19–9 (CA-19–9), and favorable RECIST imaging response. Conclusions: PDOs established from tissues obtained from patients previously receiving cytotoxic chemotherapies can be accomplished in a clinically certified laboratory. Sequencing PDOs following biomass expansion improves clinical sequencing quality. High in vitro sensitivity to standard-of-care chemotherapeutics predicts good clinical response to systemic chemotherapy in PDAC. See related commentary by Zhang et al., p. 3176
Abstract OT1-14-02: Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
Authors: Sara M Tolaney, Romualdo Barroso-Sousa, Zefei Jiang, Yeon Hee Park, Mothaffar Rimawi, Cristina Saura, Andreas Schneeweiss, Masakazu Toi, Tinghui Yu, Jagdish Shetty, Pia Herbolsheimer, Sibylle Loibl
Journal: Cancer Research (2022)

Abstract Background: A combination of a taxane, trastuzumab, and pertuzumab (THP) is the standard-of-care (SOC) 1L treatment for patients (pts) with HER2+ mBC; THP demonstrated median progression-free survival (mPFS) of 18.7 mo and overall survival (OS) of 56.5 mo (Swain et al. N Engl J Med. 2015;372:724-734). However, pts eventually develop resistance to treatment. Novel treatment options are necessary in order to delay the emergence of resistance and provide better clinical outcomes, improve quality of life (QOL), and prolong survival in the 1L setting. T-DXd has demonstrated efficacy in pts with heavily pretreated HER2+ mBC, with an objective response rate (ORR) of 61.4%, duration of response (DOR) of 20.8 mo, and mPFS of 19.4 mo (Modi et al. Cancer Res. 2021. Abstract PD3-06). Data from DESTINY-Breast01 supported global approvals of T-DXd in HER2+ mBC. Here we describe a phase 3 trial evaluating the efficacy and safety of T-DXd ± pertuzumab compared with THP in the 1L treatment of HER2+ mBC. Trial design: DESTINY-Breast09 (NCT04784715) is a global, multicenter, randomized, phase 3 trial assessing the efficacy and safety of T-DXd with or without pertuzumab compared with SOC THP as 1L treatment in pts with HER2+ (IHC 3+ or ISH+ assessed locally per ASCO-CAP guidelines and centrally confirmed) advanced or mBC. This study consists of 3 treatment arms: arm A (T-DXd + placebo), arm B (T-DXd + pertuzumab), and arm C (THP). Randomization is 1:1:1 and pts will be stratified by prior treatment status (de novo vs recurrent), hormone receptor status (positive vs negative), and PIK3CA mutation status (detected vs not detected). Pts (N≈1134) must have had no prior chemotherapy or HER2-targeted therapy for advanced or mBC (1 prior line of endocrine therapy is allowed for mBC). The primary endpoint is PFS by blinded independent central review. Secondary endpoints include PFS by investigator assessment, OS, ORR, DOR, PFS2, health-related quality of life (QOL), pharmacokinetics, immunogenicity, and safety. Citation Format: Sara M Tolaney, Romualdo Barroso-Sousa, Zefei Jiang, Yeon Hee Park, Mothaffar Rimawi, Cristina Saura, Andreas Schneeweiss, Masakazu Toi, Tinghui Yu, Jagdish Shetty, Pia Herbolsheimer, Sibylle Loibl. Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09 [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr OT1-14-02.
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampling
Authors: Tiffany G Harris, Yingfeng Wu, Lauren E Parmley, Godfrey Musuka, Munyaradzi P Mapingure, Innocent Chingombe, Owen Mugurungi, Avi Hakim, Perpetua Gozhora, Sophia S Miller, Matthew R Lamb, Chesterfield Samba, John H Rogers
Journal: The Lancet HIV (2022)
PROGNOSTIC IMPLICATIONS OF RIGHT VENTRICULAR FREE WALL STRAIN IN CARDIAC RESYNCHRONIZATION THERAPY RECIPIENTS
Authors: Jan Stassen, Xavier Galloo, Kensuke Hirasawa, Edgard A. Prihadi, Nina Ajmone Marsan, Pieter van der Bijl, Jeroen J. Bax
Journal: Journal of the American College of Cardiology (2022)
Addressing the Child Mental Health State of Emergency in Schools—Opportunities for State Policy Makers
Authors: Janet R. Cummings, Adam S. Wilk, Elizabeth H. Connors
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy
Authors: Julie Vanderpoel, Bruno Emond, Isabelle Ghelerter, Katherine Milbers, Marie-Hélène Lafeuille, Patrick Lefebvre, Lorie A Ellis
Journal: Journal of the National Comprehensive Cancer Network (2022)

"HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK‐air<sup>®</sup> real‐world data
Authors: Bernardo Sousa‐Pinto, Ana Sá‐Sousa, Rafael José Vieira, Rita Amaral, Ludger Klimek, Wienczyslawa Czarlewski, Josep M. Antó, Oliver Pfaar, Anna Bedbrook, Violeta Kvedariene, Maria Teresa Ventura, Ignacio J. Ansotegui, Karl‐Christian Bergmann, Luisa Brussino, G. Walter Canonica, Victoria Cardona, Pedro Carreiro‐Martins, Tomas Casale, Lorenzo Cecchi, Tomás Chivato, Derek K. Chu, Cemal Cingi, Elísio M. Costa, Alvaro A. Cruz, Giulia De Feo, Philippe Devillier, Wytske J. Fokkens, Mina Gaga, Bilun Gemicioğlu, Tari Haahtela, Juan Carlos Ivancevich, Zhanat Ispayeva, Marek Jutel, Piotr Kuna, Igor Kaidashev, Helga Kraxner, Désirée E. Larenas‐Linnemann, Daniel Laune, Brian Lipworth, Renaud Louis, Michael Makris, Riccardo Monti, Mario Morais‐Almeida, Ralph Mösges, Joaquim Mullol, Mikaëla Odemyr, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Milan Sova, Ana Todo‐Bom, Luis Taborda‐Barata, Peter Valentin Tomazic, Sanna Toppila‐Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Olivier Vandenplas, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, João A. Fonseca, Jean Bousquet
Journal: Allergy (2022)

Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. We analysed 2015-2020 MASK-air® European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ('VAS Global Symptoms') and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year. We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p < .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H1 -antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.
USP25 inhibition ameliorates Alzheimer’s pathology through the regulation of APP processing and Aβ generation
Authors: Qiuyang Zheng, Beibei Song, Guilin Li, Fang Cai, Meiling Wu, Yingjun Zhao, LuLin Jiang, Tiantian Guo, Mingyu Shen, Huan Hou, Ying Zhou, Yini Zhao, Anjie Di, Lishan Zhang, Fanwei Zeng, Xiu-Fang Zhang, Hong Luo, Xian Zhang, Hongfeng Zhang, Zhiping Zeng, Timothy Y. Huang, Chen Dong, Hong Qing, Yun Zhang, Qing Zhang, Xu Wang, Yili Wu, Huaxi Xu, Weihong Song, Xin Wang
Journal: Journal of Clinical Investigation (2022)

Down syndrome (DS), or trisomy 21, is one of the critical risk factors for early-onset Alzheimer's disease (AD), implicating key roles for chromosome 21-encoded genes in the pathogenesis of AD. We previously identified a role for the deubiquitinase USP25, encoded on chromosome 21, in regulating microglial homeostasis in the AD brain; however, whether USP25 affects amyloid pathology remains unknown. Here, by crossing 5×FAD AD and Dp16 DS mice, we observed that trisomy 21 exacerbated amyloid pathology in the 5×FAD brain. Moreover, bacterial artificial chromosome (BAC) transgene-mediated USP25 overexpression increased amyloid deposition in the 5×FAD mouse brain, whereas genetic deletion of Usp25 reduced amyloid deposition. Furthermore, our results demonstrate that USP25 promoted β cleavage of APP and Aβ generation by reducing the ubiquitination and lysosomal degradation of both APP and BACE1. Importantly, pharmacological inhibition of USP25 ameliorated amyloid pathology in the 5×FAD mouse brain. In summary, we identified the DS-related gene USP25 as a critical regulator of AD pathology, and our data suggest that USP25 serves as a potential pharmacological target for AD drug development.
DEEP LEARNING-BASED PREDICTION OF RIGHT VENTRICULAR EJECTION FRACTION USING 2D ECHOCARDIOGRAMS
Authors: Marton Tokodi, Balint Magyar, Andras Soos, Mate Tolvaj, Bálint Károly Lakatos, Alexandra Fabian, Mark Bence Szigeti, Bela Merkely, Andras Horvath, Attila Kovács
Journal: Journal of the American College of Cardiology (2022)
Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation
Authors: Anna R Yousaf, Margaret M Cortese, Allan W Taylor, Karen R Broder, Matthew E Oster, Joshua M Wong, Alice Y Guh, David W McCormick, Satoshi Kamidani, Elizabeth P Schlaudecker, Kathryn M Edwards, C Buddy Creech, Mary A Staat, Ermias D Belay, Paige Marquez, John R Su, Mark B Salzman, Deborah Thompson, Angela P Campbell, Oidda Museru, Leigh M. Howard, Monica Parise, John J. Openshaw, Chloe LeMarchand, Lauren E. Finn, Moon Kim, Kiran V. Raman, Kenneth K. Komatsu, Bryce L. Spiker, Cole P. Burkholder, Sean M. Lang, Jonathan H. Soslow
Journal: The Lancet Child & Adolescent Health (2022)
Human Infection with an Avian-Origin Influenza A (H10N3) Virus
Authors: Xian Qi, Haibo Qiu, Shixuan Hao, Fengcai Zhu, Yingzi Huang, Ke Xu, Huiyan Yu, Daowei Wang, Lei Zhou, Qigang Dai, Yin Zhou, Shenjiao Wang, Haodi Huang, Shuyue Yu, Xiang Huo, Kai Chen, Jin Liu, Jianli Hu, Ming Wu, Changjun Bao
Journal: New England Journal of Medicine (2022)
Toward Simpler, Safer Treatment of Cryptococcal Meningitis
Authors: Mahomed-Yunus S. Moosa, Richard J. Lessells
Journal: New England Journal of Medicine (2022)

Cryptococcal meningitis is one of the most common and serious human immunodeficiency virus (HIV)–related opportunistic infections among adults in sub-Saharan Africa, leading to an estimated 135,900 deaths every year.1 Under the best conditions, cryptococcal meningitis is a challenge to manage and involves high-quality medical and nursing care and often prolonged hospitalization. Much of this is driven by the fact that the best outcomes are seen when the key antifungal agent, amphotericin B, is administered intravenously daily for 1 or 2 weeks.2 However, treatment with amphotericin B–based regimens frequently results in substantial toxic effects, including blood dyscrasias, acute kidney injury, electrolyte . . .
Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications
Authors: Jérôme Boursier, Clémence M. Canivet, Charlotte Costentin, Adrien Lannes, Adèle Delamarre, Nathalie Sturm, Brigitte Le Bail, Sophie Michalak, Frédéric Oberti, Marie-Noelle Hilleret, Marie Irles-Depé, Isabelle Fouchard, Paul Hermabessiere, Justine Barthelon, Paul Calès, Bertrand Cariou, Victor de Ledinghen, Marine Roux
Journal: Clinical Gastroenterology and Hepatology (2022)
COMPREHENSIVE NUTRIENT CONSUMPTION AND METABOLIC PROFILING DURING KETOGENIC DIET AND RELATIONSHIP WITH MYOCARDIAL GLUCOSE UPTAKE ON FDG-PET
Authors: Senthil Selvaraj, Sara Seidelmann, Meshal Soni, Abhijit Bhattaru, Kenneth B. Margulies, Svati Shah, Supritha Dugyala, Chenao Qian, Daniel Pryma, Zoltan P. Arany, Daniel P. Kelly, Julio A. Chirinos, Paco E. Bravo
Journal: Journal of the American College of Cardiology (2022)
REVEAL LITE 2 SCORE RELIABLY PREDICTS ONE-YEAR MORTALITY IN PULMONARY HYPERTENSION
Authors: Jay Jalenak, Danh Tran, Noura Alturaif, Younghoon Kwon, James D. Bergin, Mohammad Abuannadi, David Shisler, Steven Philips, Nishaki Mehta, Andrew Mihalek, Kenneth C. Bilchick, Sula Mazimba
Journal: Journal of the American College of Cardiology (2022)
Long-term Air Pollution Exposure and Pneumonia-related Mortality in a Large Pooled European Cohort
Authors: Shuo Liu, Youn-Hee Lim, Jie Chen, Maciek Strak, Kathrin Wolf, Gudrun Weinmayr, Sophia Rodopolou, Kees de Hoogh, Tom Bellander, Jørgen Brandt, Hans Concin, Emanuel Zitt, Daniela Fecht, Francesco Forastiere, John Gulliver, Ole Hertel, Barbara Hoffmann, Ulla A. Hvidtfeldt, W. M. Monique Verschuren, Karl-Heinz Jöckel, Jeanette T. Jørgensen, Rina So, Heresh Amini, Thomas Cole-Hunter, Amar J. Mehta, Laust H. Mortensen, Matthias Ketzel, Anton Lager, Karin Leander, Petter Ljungman, Gianluca Severi, Marie-Christine Boutron-Ruault, Patrik K. E. Magnusson, Gabriele Nagel, Göran Pershagen, Annette Peters, Ole Raaschou-Nielsen, Debora Rizzuto, Yvonne T. van der Schouw, Sara Schramm, Mette Sørensen, Massimo Stafoggia, Anne Tjønneland, Klea Katsouyanni, Wei Huang, Evangelia Samoli, Bert Brunekreef, Gerard Hoek, Zorana J. Andersen
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: Ambient air pollution exposure has been linked to mortality from chronic cardiorespiratory diseases, while evidence on respiratory infections remains more limited. Objectives: We examined the association between long-term exposure to air pollution and pneumonia-related mortality in adults in a pool of eight European cohorts. Methods: Within the multicenter project ELAPSE (Effects of Low-Level Air Pollution: A Study in Europe), we pooled data from eight cohorts among six European countries. Annual mean residential concentrations in 2010 for fine particulate matter, nitrogen dioxide (NO2), black carbon (BC), and ozone were estimated using Europe-wide hybrid land-use regression models. We applied stratified Cox proportional hazard models to investigate the associations between air pollution and pneumonia, influenza, and acute lower respiratory infections (ALRI) mortality. Measurements and Main Results: Of 325,367 participants, 712 died from pneumonia and influenza combined, 682 from pneumonia, and 695 from ALRI during a mean follow-up of 19.5 years. NO2 and BC were associated with 10-12% increases in pneumonia and influenza combined mortality, but 95% confidence intervals included unity (hazard ratios, 1.12 [0.99-1.26] per 10 μg/m3 for NO2; 1.10 [0.97-1.24] per 0.5 10-5m-1 for BC). Associations with pneumonia and ALRI mortality were almost identical. We detected effect modification suggesting stronger associations with NO2 or BC in overweight, employed, or currently smoking participants compared with normal weight, unemployed, or nonsmoking participants. Conclusions: Long-term exposure to combustion-related air pollutants NO2 and BC may be associated with mortality from lower respiratory infections, but larger studies are needed to estimate these associations more precisely.
THE NOVEL USE OF IV INOTROPE THERAPY IN THE OUTPATIENT SETTING AS A BRIDGE-TORECOVERY IN ADVANCED HEART FAILURE TREATED WITH SACUBITRIL-VALSARTAN
Authors: Damir Vukomanovic, Hayley Mitchel, Kyrah Berthiaume, Paul Paralinghug, Anantharam V. Kalya, Francisco Arabia, Radha Gopalan
Journal: Journal of the American College of Cardiology (2022)
Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
Authors: Grace Mantus, Lindsay E. Nyhoff, Venkata-Viswanadh Edara, Veronika I. Zarnitsyna, Caroline R. Ciric, Maria W. Flowers, Carson Norwood, Madison Ellis, Laila Hussaini, Kelly E. Manning, Kathy Stephens, Evan J. Anderson, Rafi Ahmed, Mehul S. Suthar, Jens Wrammert
Journal: Cell Reports Medicine (2022)

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic highlights the importance of determining the breadth and durability of humoral immunity to SARS-CoV-2 mRNA vaccination. Herein, we characterize the humoral response in 27 naive and 40 recovered vaccinees. SARS-CoV-2-specific antibody and memory B cell (MBC) responses are durable up to 6 months, although antibody half-lives are shorter for naive recipients. The magnitude of the humoral responses to vaccination strongly correlates with responses to initial SARS-CoV-2 infection. Neutralization titers are lower against SARS-CoV-2 variants in both recovered and naive vaccinees, with titers more reduced in naive recipients. While the receptor-binding domain (RBD) is the main neutralizing target of circulating antibodies, Moderna-vaccinated naives show a lesser reliance on RBDs, with >25% neutralization remaining after depletion of RBD-binding antibodies. Overall, we observe that vaccination induces higher peak titers and improves durability in recovered compared with naive vaccinees. These findings have broad implications for current vaccine strategies deployed against the SARS-CoV-2 pandemic.
C‐C motif chemokine ligand 5 confines liver regeneration by down‐regulating reparative macrophage‐derived hepatocyte growth factor in a forkhead box O 3a–dependent manner
Authors: Miao Huang, Junzhe Jiao, Hao Cai, Yichi Zhang, Yuhan Xia, Jiacheng Lin, Zhi Shang, Yihan Qian, Fang Wang, Hailong Wu, Xiaoni Kong, Jinyang Gu
Journal: Hepatology (2022)

Abstract Background and Aims Liver regeneration (LR) is vital for the recovery of liver function after hepatectomy. Limited regeneration capacity, together with insufficient remnant liver volume, is a risk factor for posthepatectomy liver failure (PHLF) resulting from small‐for‐size syndrome. Although inflammation plays an important role in controlling LR, the underlying mechanisms still remain obscure. Approach and Results We identified C‐C motif chemokine ligand (CCL) 5 as an important negative regulator for LR. CCL5 levels were elevated after partial hepatectomy (PHx), both in healthy donors of living donor liver transplantation (LT) and PHx mouse models. Ccl5 knockout mice displayed improved survival after 90% PHx and enhanced LR 36 h after 70% PHx. However, primary hepatocytes from Ccl5−/− mice exposed to growth factors in vitro showed no proliferation advantage compared to those from wild‐type (WT) mice. Flow cytometry analysis showed that proportions of Ly6C lo macrophages were significantly increased in Ccl5−/− mice after 70% PHx. RNA‐sequencing analysis revealed that sorted macrophages (CD11b + Ly6C lo&amp;hi ) manifested enhanced expression of reparative genes in Ccl5−/− mice compared to WT mice. Mechanistically, CCL5 induced macrophages toward proinflammatory Ly6C hi phenotype, thereby inhibiting the production of hepatocyte growth factor (HGF) through the C‐C motif chemokine receptor (CCR) 1– and CCR5‐mediated forkhead box O (FoxO) 3a pathways. Finally, blockade of CCL5 greatly optimized survival and boosted LR in the mouse PHx model. Conclusions Our findings suggest that inhibition of CCL5 is a promising strategy to improve regeneration restoration by enhancing HGF secretion from reparative macrophages through the FoxO3a pathway, which may potentially reduce the mortality of PHLF.